Tumor-associated macrophages (TAMs) are critical components of the ovarian cancer microenvironment, promoting tumor growth, immune evasion, and metastasis. Targeting TAMs presents a promising strategy in immuno-oncology to improve the efficacy of existing treatments and develop new therapeutic approaches. Ongoing research and clinical trials are actively trying to further clarify the roles of TAMs and optimize strategies for modulating their function in ovarian cancer. Ovarian cancer cells secrete chemokines (e.g., CCL2, CCL5) and cytokines (e.g., CSF-1, IL-6) that recruit and polarize macrophages to the tumor site. Furthermore, they play a role in tumor progression: (i) TAMs inhibit T cell function and promote regulatory T (Treg) cells, facilitating immune evasion; (ii) TAMs secrete pro-angiogenic factors such as vascular endothelial growth factor (VEGF), promoting blood vessel formation; (iii) TAMs facilitate metastasis by degrading the extracellular matrix and promoting cancer cell invasion. The TAMs | ovarian cancer co-occurrence has been observed in a fair number of papers with an average fold increase in publications being between 3.5-to 4-fold for the period 2020-2022 (Figure ) to qualify it is an emerging topic. Similar to other identified concept pairs, the TAMs | ovarian cancer pair shows a 7-fold increase in publications from 2021 to 2022 (Supporting Information S1).